Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients.
暂无分享,去创建一个
Toshio Miyata | T. Miyata | K. Asahi | Tsuyoshi Watanabe | Tetsuo Katoh | Tsuyoshi Watanabe | Koichi Asahi | Kenichi Tanaka | Yoshihiro Tani | Jun Asai | Fumihiko Nemoto | Yuki Kusano | Hodaka Suzuki | Yoshimitsu Hayashi | Yoshihiro Tani | Kenichi Tanaka | Y. Hayashi | T. Katoh | Hodaka Suzuki | Jun Asai | Y. Kusano | F. Nemoto
[1] M. Jadoul,et al. Preparing renal replacement therapy in stage 4 CKD patients referred to nephrologists: a difficult balance between futility and insufficiency. A cohort study of 386 patients followed in Brussels. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] T. Hashimoto,et al. Advanced glycation end products in nondiabetic patients with coronary artery disease. , 2001, Diabetes care.
[3] R. Foley,et al. Epidemiology of cardiovascular disease in chronic renal disease , 2000 .
[4] D. Levy,et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. , 1999, Kidney international.
[5] D. Hricik,et al. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. , 1996, Clinical transplantation.
[6] T. Miyata,et al. Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods , 2007, Rheumatology International.
[7] E. Friedman,et al. Advanced glycosylation end products in patients with diabetic nephropathy. , 1991, The New England journal of medicine.
[8] U. Ott,et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. , 2004, Kidney international.
[9] C van Ypersele de Strihou,et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. , 1996, Journal of the American Society of Nephrology : JASN.
[10] T. Miyata,et al. Relationship of Skin Autofluorescence to Cardiovascular Disease in Japanese Hemodialysis Patients , 2009, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[11] H. Wulf,et al. Autofluorescence of human skin is age-related after correction for skin pigmentation and redness. , 2001, The Journal of investigative dermatology.
[12] M. Nangaku,et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. , 2002, Journal of the American Society of Nephrology : JASN.
[13] R. Poveda,et al. Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[14] A. Smit,et al. Simple Noninvasive Measurement of Skin Autofluorescence , 2005, Annals of the New York Academy of Sciences.
[15] A. Smit,et al. A tool to identify type 2 diabetic patients at risk for developing microvascular complications , 2008 .
[16] Kdoqi Disclaimer. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] C. Wanner,et al. Advanced glycation end products and mortality in hemodialysis patients. , 2002, Kidney international.
[18] T. Miyata,et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. , 1998, Journal of the American Society of Nephrology : JASN.
[19] R. Petersen,et al. Clinical Subtypes of Alzheimer’s Disease , 1998, Dementia and Geriatric Cognitive Disorders.
[20] T. Miyata,et al. Advanced glycation end products in patients with cerebral infarction. , 2009, Internal medicine.
[21] S. Devaraj,et al. Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease , 2002, Current opinion in nephrology and hypertension.
[22] Reindert Graaff,et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.
[23] R. Gans,et al. Simple non-invasive assessment of advanced glycation endproduct accumulation , 2004, Diabetologia.
[24] N. Powe,et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. , 2002, Journal of the American Society of Nephrology : JASN.
[25] S. Fukumoto,et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. , 2008, Metabolism: clinical and experimental.
[26] T. Miyata,et al. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? , 1998, Kidney international.
[27] Yasuhiko Tomino,et al. Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[28] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[29] A. Smit,et al. AGEs, autofluorescence and renal function. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[30] C. Elmets,et al. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. , 1986, The New England journal of medicine.
[31] T. Miyata,et al. Carbonyl Stress: Increased Carbonyl Modification of Proteins by Autoxidation Products of Carbohydrates and Lipids in Uremia , 1999, The International journal of artificial organs.
[32] C. Gullion,et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. , 2004, Archives of internal medicine.
[33] Bertram L Kasiske,et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.